Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03454451
Title CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Corvus Pharmaceuticals, Inc.
Indications

renal cell carcinoma

triple-receptor negative breast cancer

urinary bladder cancer

colorectal cancer

uterine cancer

sarcoma

prostate cancer

cervical cancer

endometrial cancer

lung non-small cell carcinoma

Therapies

CPI-006

CPI-006 + Pembrolizumab

CPI-006 + CPI-444

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.